Medasense awarded a development grant to extend application of NOL monitoring for noncommunicating dementia patients.
MedTech Innovator selected Medasense for its innovation and accomplishments, as one of 50 top companies to present at the 2019 Showcase in San Francisco.
Medasense’s NOL technology for nociception monitoring is now compatible with Philips IntelliVue patient monitors.
Medasense announces positive results from clinical studies, evaluating the role of NOL technology in guiding opioid administration during surgery for improved outcomes.
NOL in Australia:
We are happy to share with you that Medasense received approval to market the PMD-200™ system in Australia, strengthening commercial presence around the world.
We are proud to share with you that the trademark "NOL NOCICEPTION LEVEL INDEX" is approved and registered as Medasense's trademark in Europe and in the U.S.!
Medasense won the 2017 Center of Excellence in Wireless and Information Technology (CEWIT) Startup Contest at State University of New York, Stonybrook! (more…)
We are excited to share that Medasense’s NOL technology was chosen to be highlighted in the British Journal of Anaesthesia (BJA) review article “Digital innovations and emerging technologies for enhanced recovery programmes”.
We are pleased to share with you the exciting news that Medasense has received AMAR approval to sell our pain (Nociception) monitoring system in Israel! Israeli anaesthesiologists are now able…
CEO Galit Zuckerman-Stark writes in Innovations in Pharmaceutical Technology how Medasense's innovation provides an objective approach that could help healthcare professionals better assess pain. To read the full article click…